Stereotactic body radiotherapy for lung metastases as oligo-recurrence: A single institutional study

The purpose of this study was to investigate clinical outcomes following stereotactic body radiotherapy (sbrt) for lung metastases as oligo-recurrence. from may 2003 to june 2014,records for 66 patients with 76 oligo-recurrences in the lungs treated with sbrt were retrospectively reviewed. oligo-recurrence primary sites and patient numbers were as follows: lungs,31; colorectal,13; head and neck,10; esophagus,3; uterus,3; and others,6. the median sbrt dose was 50 gy (range,45-60 gy) administered in a median of 5 (range,5-9) fractions. all patients received sbrt,with no acute toxicity. surviving patients had a median follow-up time of 36.5 months. the 3-year rates of local control,overall survival and disease-free survival were 90.6%,76.0% and 53.7%,respectively. longer disease-free interval from initial treatment to sbrt,and non-colorectal cancer were both associated with favorable outcomes. disease progression after sbrt occurred in 31 patients,most with distant metastases (n = 24) [among whom,87.5% (n = 21) had new lung metastases]. among these 21 patients,12 were judged as having a second oligo-recurrence. additional sbrt was performed for these 12 patients,and all 12 tumors were controlled without disease progression. three patients (4.5%) developed grade 2 radiation pneumonitis. no other late adverse events of grade ≥2 were identified. thus,sbrt for oligo-recurrence achieved acceptable tumor control,with additional sbrt also effective for selected patients with a second oligo-recurrence after primary sbrt. © 2015 the author 2015.